BTC$62,495.00-2.10%
ETH$1,662.50-3.31%
USDT$0.99890.00%
BNB$576.53-2.03%
USDC$0.9998-0.01%
XRP$1.11-1.51%
SOL$69.43-3.23%
TRX$0.329-1.30%
FIGR_HELOC$1.03-0.16%
HYPE$62.14-5.95%
DOGE$0.0788-3.89%
USDS$0.9997+0.01%
RAIN$0.0156-2.27%
LEO$9.54+0.05%
ZEC$416.96-5.64%
XLM$0.1953-3.57%
BTC$62,495.00-2.10%
ETH$1,662.50-3.31%
USDT$0.99890.00%
BNB$576.53-2.03%
USDC$0.9998-0.01%
XRP$1.11-1.51%
SOL$69.43-3.23%
TRX$0.329-1.30%
FIGR_HELOC$1.03-0.16%
HYPE$62.14-5.95%
DOGE$0.0788-3.89%
USDS$0.9997+0.01%
RAIN$0.0156-2.27%
LEO$9.54+0.05%
ZEC$416.96-5.64%
XLM$0.1953-3.57%
Nukkleus Inc. shares surged in pre-market trading as the aerospace and defense company announces a strategic European joint venture.
Outlook Therapeutics stock crashed 70% in premarket after the FDA rejected its wet AMD drug application, citing insufficient efficacy evidence despite previous trial successes.
Kohl's stock surged 23% after reporting Q2 adjusted EPS of 56 cents versus 29 cents expected, while raising full-year guidance and completing its Sephora rollout across…
Firefly Neuroscience stock surged 31% after unveiling its CLEAR platform powered by Nvidia GPUs.
HCW Biologics stock surged 85.5% after announcing a breakthrough second-generation immune checkpoint inhibitor that outperformed existing cancer treatments.
MIT’s “GenAI Divide” report has been somewhat misinterpreted in ways that spooked investors and sent tech markets tumbling.
Intel’s fate is increasingly tied to geopolitics as it stands beside - and against - TSMC in shaping the U.S. tech stack.
Target's stock dropped over 10% premarket after reporting Q2 earnings and announcing a new CEO transition.
Amazon expands same-day grocery delivery to 1,000+ cities with plans to reach 2,300 by year-end.
Many of Cathie Wood’s bets have turned sour. Is The Trade Desk another one in the making?
Tesla stock gains 3.87% following robotaxi permit approval in Texas and UK energy license application.
Fortified by Toyota capital inflows, Joby Aviation is making all the right moves to launch a global air taxi service.
Abivax shares surged over 400% in premarket trading after announcing positive Phase 3 results for its ulcerative colitis drug obefazimod.